Evidence map›Paper›PMID 26765533›Full record

ArticleAIDS research and human retroviruses2016

Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.

Sergey Iordanskiy, Fatah Kashanchi

Open access · bronzeAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sergey Iordanskiy1 National Center for Biodefense and Infectious Diseases, George Mason University , Manassas, Virginia.
Fatah Kashanchi2 Laboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, Virginia.
George Mason University · US

Funding

HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVESR01AI043894 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KASHANCHI, FATAH · 1999 to 2015
$4.4M
Effect of novel cdk9 inhibitor on HIV transcriptionR21AI114490 · NIAID · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2014 to 2015
$428k
Nanotrap particle-based assay to quantify HIV-1 in latently-infected T cellsR21AI113140 · NIAID · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2014 to 2015
$409k
NIAID NIH HHS AI043894NIAID NIH HHS AI113140NIAID NIH HHS AI114490
6 · The paper itself

Abstract

The use of highly active antiretroviral therapy against HIV-1 for last two decades has reduced mortality of patients through extension of nonsymptomatic phase of infection. However, HIV-1 can be preserved in long-lived resting CD4(+) T cells, which form a viral reservoir in infected individuals, and potentially in macrophages and astrocytes. Reactivation of viral replication is critical since the host immune response in combination with antiretroviral therapy may eradicate the virus (shock and kill strategy). In this opinion piece, we consider potential application of therapeutic doses of irradiation, the well-known and effective stress signal that induces DNA damage and activates cellular stress response, to resolve two problems: activate HIV-1 replication and virion production in persistent reservoirs under cART and deplete infected cells through selective cell killing using DNA damage responses.

Indexed as

Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4-Positive T-LymphocytesDNA DamageDNA RepairHIV-1HIV InfectionsHumansVirus ActivationVirus LatencyVirus ReplicationAnti-HIV Agents

Identifiers

PMID26765533
PMCPMC4761804
OpenAlexW2234306214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.